MedPath

Honz Pharmaceutical Co., Ltd.

Honz Pharmaceutical Co., Ltd. logo
🇨🇳China
Ownership
Public, Subsidiary
Established
1994-01-20
Employees
255
Market Cap
-
Website
http://www.honz.com.cn
Introduction

The company is a listed enterprise focusing on children's health. It is a national high-tech enterprise, and has pioneered the establishment of an enterprise postdoctoral research workstation with children's medicine as the main research direction. The company adheres to the corporate tenet of “good medicine, bless humanity”, actively implements the “Children's Health Strategy” and “Quality Strategy”, and ingeniously builds a national brand in the children's health industry. The company is a leading domestic children's health enterprise whose main business is the R&D, production and sales of children's medicines, maternal and child health products, and medical devices such as medical protective equipment. Main products: Respiratory medicine, digestive medicine, anti-allergic drugs, antibiotics, nutritional supplements, antibacterial and antiviral drugs, antipyretic and analgesic drugs, gynecological drugs, masks, etc. Corporate honors: Top 500 Asian Brands, the 8th Hainan Excellent Enterprise, etc. Won the honorary certificate of “Guangdong High-tech Product”, the title of “Top 100 Pharmaceutical Digital Brands”, “2022 Growth Potential Star” Company, “Leading Force - High-Quality Pharmaceutical Development Achievement Enterprise in China”, the 2023 Hainan Top 40 Manufacturing Enterprises List, the “Health Industry's Most Growing Listed Company” Award, the 2023 “Excellent ESG Case of Hainan Listed Companies”, the “2023 Haikou 'Trade Union Cup' Pharmaceutical Industry Worker Labor Skills Competition - Second Prize in the Chemical Inspection and Operation Skills Competition”, and “Guangdong Provincial Enterprise Technology Honors such as “Center” and “Famous Brand Product of Guangdong Province”.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

61

NMPA:61

Drug Approvals

Ibuprofen Granules

Product Name
布洛芬颗粒
Approval Number
国药准字H20205037
Approval Date
Oct 16, 2024
NMPA

Cimetidine Tablets

Product Name
西咪替丁片
Approval Number
国药准字H46020458
Approval Date
Aug 6, 2024
NMPA

小青龙颗粒

Approval Number
国药准字Z44021042
Approval Date
Jul 30, 2024
NMPA

Berberine Hydrochloride Tablets

Product Name
盐酸小檗碱片
Approval Number
国药准字H44023561
Approval Date
Jul 30, 2024
NMPA

Terbutaline Sulfate Tablets

Product Name
硫酸特布他林片
Approval Number
国药准字H46020459
Approval Date
Jul 26, 2024
NMPA

Cefpodoxime Proxetil Tablets

Product Name
西博特欣
Approval Number
国药准字H20030591
Approval Date
Jul 22, 2024
NMPA

Cefminox Sodium for Injection

Product Name
注射用头孢米诺钠
Approval Number
国药准字H20066371
Approval Date
Jul 19, 2024
NMPA

Cefminox Sodium for Injection

Product Name
注射用头孢米诺钠
Approval Number
国药准字H20056644
Approval Date
Jul 19, 2024
NMPA

Cefminox Sodium for Injection

Product Name
注射用头孢米诺钠
Approval Number
国药准字H20065862
Approval Date
Jul 19, 2024
NMPA

Cefminox Sodium for Injection

Product Name
注射用头孢米诺钠
Approval Number
国药准字H20066353
Approval Date
Jul 19, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.